(Q52034593)
Statements
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416 (English)
Afshin Dowlati
Kelly Robertson
John Waas
Nicholas P Ziats
Paul Hartman
Fadi W Abdul-Karim
Jay K Wasman
Jack Jesberger
Jonathan Lewin
Keith McCrae
Percy Ivy